Novo Nordisk battling $3.9 billion TP adjustment on transfer of biopharmaceutical division

Denmark's largest listed company, Novo Nordisk, has been hit with transfer pricing adjustments of DKK 22 billion ($3.95 billion) by the Danish tax authority (SKAT) resulting in an increased tax bill of DKK 5.5 billion.

Locked content

The article you are trying to view is only available to subscribers and current trialists